Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK ® (vanzacaftor ...
Moby Strategic Execution and Portfolio Diversification. Management attributes Q1 performance to strong executio ...
Over the past three decades, meaningful progress has been made in the research and understanding of cystic fibrosis (CF). 1 ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the most profitable biotech stocks to buy now. On April 13, ...
May 4 (Reuters) - Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a ...
Over the 3 months period, Vertex Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 9.5 ...
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced the ...
By Leslie Herod Since its inception, Colorado’s Prescription Drug Affordability Board (PDAB) created fear among patients ...
By Leslie Herod Since its inception, Colorado’s Prescription Drug Affordability Board (PDAB) created fear among patients ...
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results